58.9 F
New York
Friday, April 12, 2024

Two NYU-Langone Cancer Docs Sanctioned by NYS for ‘Inappropriately’ Prescribing Meds

Related Articles


Must read

Two NYU-Langone Cancer Docs Sanctioned by NYS for ‘Inappropriately’ Prescribing Meds

 By: Benyamin Davidsons

The state of New York has sanctioned two prestigious cancer doctors, in the NYU Langone hospital system, for “inappropriately” prescribing controlled substances, as per state Department of Health documents.

As reported by the NY Post, Dr. Tibor Moskovits and Dr. Bruce Raphael allegedly prescribed drugs and failed to file appropriate records for the patients.  Between 2015 and 2017, there were allegedly three patients who allegedly got unsanctioned meds from Dr. Moskovits, state records allege.  Dr. Raphael is charged concerning one patient between 2014 and 2018, the documents show.  As a result, the state had both doctors’ medical licenses limited permanently, to keep them from prescribing controlled substances to themselves, their friends, family, co-workers, or anyone else whom they don’t have a physician-patient relationship with, as per state records.  Each of them were given a penalty of a censure and reprimand by the state Board for Professional Medical Conduct, and have been asked to take continuing education courses. Also, Dr. Moskovits was fined $750.

Dr. Raphael, 72, is the site director for NYU Langone’s Perlmutter Cancer Center.  With over 47 years of experience, he specializes in blood disorders including platelet disorders, anemia and cancers such as leukemia, lymphoma, and multiple myeloma, as per an online biography on the hospital website.

Dr. Moscovits is also a top-rated oncologist, with 38 years of experience, specializing in Hematology, with a special focus on Lymphoma, Lymphoma, Non-Hodgkin’s and Cutaneous T-Cell Lymphoma, as per an online bio.   He has authored seven research publications on topics including, “SARS-CoV-2 vaccination in non-Hodgkin lymphoma and CLL patients”,  “Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)”, and “Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma”.

A representative for NYU Langone declined to comment.  Dr. Raphael declined to comment for the Post.  Dr. Moskovits did not reply to a request for comment.

NYU Langone’s Perlmutter Cancer Center is located at240 East 38th Street in Manhattan, between Second and Third Avenue, on the 18th, 19th and 20th floors.  It boasts offering world class cancer care as part of New York’s #1 Hospital The National Cancer Institute conducts “clinical research studies to advance discoveries to prevent, diagnose, and treat cancer. We also study the prevention, patterns, causes, and control of cancer in diverse populations to improve public health and policy.

NYU Langone’s core research facilities support our investigators by providing expertise in advanced research techniques and state-of-the-art technologies. Together, we are working to cure cancer in our lifetime,” reads the hospital website.  The center now has 20 locations across Manhattan, Brooklyn, Queens, and Long Island. NYU Langone’s Faculty Group Practice (FGP) members are a group of more than 3,000 doctors employed by NYU Langone.



balance of natureDonate

Latest article

- Advertisement -